{
  "guideline": {
    "id": "PA166104972",
    "name": "Annotation of DPWG Guideline for imipramine and CYP2D6",
    "objCls": "Guideline Annotation",
    "source": "DPWG",
    "version": 33,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104972",
    "relatedChemicals": [
      {
        "id": "PA449969",
        "name": "imipramine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302502",
      "name": "Recommendation Annotation PA166302502",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104081,
        "html": "<p>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302462",
      "name": "Recommendation Annotation PA166302462",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104041,
        "html": "<p>The guideline does not provide a recommendation for imipramine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on imipramine."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302466",
      "name": "Recommendation Annotation PA166302466",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104045,
        "html": "<p>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302501",
      "name": "Recommendation Annotation PA166302501",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104080,
        "html": "<p>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302417",
      "name": "Recommendation Annotation PA166302417",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103996,
        "html": "<p>Use 30% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and the active metabolite desipramine."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302461",
      "name": "Recommendation Annotation PA166302461",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104040,
        "html": "<p>The guideline does not provide a recommendation for imipramine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on imipramine."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302465",
      "name": "Recommendation Annotation PA166302465",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104044,
        "html": "<p>The guideline does not provide a recommendation for imipramine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on imipramine."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302443",
      "name": "Recommendation Annotation PA166302443",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104022,
        "html": "<p>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and desipramine."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302421",
      "name": "Recommendation Annotation PA166302421",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104000,
        "html": "<p>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and desipramine."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302482",
      "name": "Recommendation Annotation PA166302482",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104061,
        "html": "<p>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302464",
      "name": "Recommendation Annotation PA166302464",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104043,
        "html": "<p>The guideline does not provide a recommendation for imipramine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on imipramine."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302442",
      "name": "Recommendation Annotation PA166302442",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104021,
        "html": "<p>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and desipramine."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302468",
      "name": "Recommendation Annotation PA166302468",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104047,
        "html": "<p>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302481",
      "name": "Recommendation Annotation PA166302481",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104060,
        "html": "<p>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302503",
      "name": "Recommendation Annotation PA166302503",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104082,
        "html": "<p>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302463",
      "name": "Recommendation Annotation PA166302463",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104042,
        "html": "<p>The guideline does not provide a recommendation for imipramine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on imipramine."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302441",
      "name": "Recommendation Annotation PA166302441",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104020,
        "html": "<p>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.</p>\n"
      },
      "implications": [
        "The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and desipramine."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302467",
      "name": "Recommendation Annotation PA166302467",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104046,
        "html": "<p>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>\n<p>If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</p>\n"
      },
      "implications": [
        "The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
    }
  ],
  "version": "2024-03-08-14-34"
}